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Abstract
Background: Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity
and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration
with saline are being prescribed to prevent renal deterioration in these high risk patients, their efficacy is not
clearly defined and debatable. Therefore additional prophylactic pretreatments are needed.
Methods/Design: The present study aims to investigate differences in occurrence of CIN after sarpogrelate
premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical
diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) routine treatment
without sarpogrelate, and (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary
outcome is the occurrence of CIN during 4 weeks after receiving contrast agent.
Discussion: As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in
preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide
a safe, easy and inexpensive treatment option.
Trial registration: NCT01165567
Background
Contrast-induced nephropathy (CIN) is a common form
of hospital-acquired acute renal failure (ARF) after cor-
onary angiography (CAG) and percutaneous coronary
intervention (PCI) and is associated with prolonged hos-
pitalization and adverse clinical outcomes [1,2]. Patients
undergoing PCI have a higher mortality rate if the
nephropathy develops [3]. Although its incidence is low
in patients with normal renal function, it can be much
higher in those with renal insufficiency at baseline [4,5].
Adequate prophylaxis is needed to reduce the higher
morbidity and mortality associated with CIN in high-
risk patients. A variety of therapeutic interventions,
including saline hydration, diuretics, mannitol, calcium
channel antagonists, theophylline, endothelin receptor
antagonists, and dopamine, have been used in an
attempt to prevent CIN [6-9]. Hydration with normal
saline solution is the most widely accepted preventive
intervention [9,10]. But the nephropathy occurred in
20~30% who received the recommend treatment
[11,12], it means current treatments are not enough and
the optimal strategy to prevent CIN has not been
established.
Although the pathogenesis of this condition is not
fully understood, it is most likely the result of renal
ischemia and direct toxicity to tubular epithelial cells
[13,14]. After contrast is injected, renal blood flow tran-
siently increases and then decreases over a longer time,
suggesting that renal ischemia is a major factor in the
pathogenesis of CIN [13]. Contrast agents reduce the
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Many studies suggest that contrast agents are directly
toxic to kidney cells, causing proximal cell vacuolization,
interstitial inflammation, cellular necrosis, and enzy-
muria [15].
Sarpogrelate is a selective 5-hydroxytryptamine recep-
tor subtype 2A (5-HT2A) antagonist that inhibits
responses to 5-HT mediated by 5-HT2A receptors such
as platelet aggregation, vasoconstriction, and vascular
smooth muscle proliferation [16-18]. Its chemical struc-
ture is illustrated in Figure 1. Several studies demon-
strated that sarpogrelate is efficacious treatment in
thrombosis, coronary artery spasm, atherosclerosis, rest-
enosis, peripheral artery disease, diabetes and kidney
disease [16,17,19-23]. Especially small clinical trial had
shown that sarpogrelate has a renal protective potential
[23,24]. A pilot study demonstrated that sarpogrelate
improved the symptoms and signs of diabetic nephropa-
thy and neuropathy in three of eight patients with
Type 2 diabetes and mild nephropathy [25]. Sarpogrelate
also reduced the urinary and plasma levels of thrombox-
ane A2 and this may be associated with the reduced
albumin excretion [26]. Another study demonstrated
that sarpogrelate reduced albuminuria in diabetic
patients with early-stage diabetic nephropathy within 3
months [27]. Therefore, we might hypothesize that sar-
pogrelate would have shown positive results in prophy-
laxis of CIN.
The primary hypothesis to be tested is whether sarpo-
grelate significantly reduce the occurrence of CIN dur-
ing 4 weeks follow-up period, compared with the
control group.
Methods/Design
The study is designed as a non-blinded, prospective, ran-
domized controlled clinical trial to evaluate efficacy and
safety of sarpogrelate in CKD patients undergoing CAG
and PCI. After a baseline measurement, participants were
randomly allocated into the treatment group (routine
treatment with sarpogrelate) or the control group
(routine treatment without sarpogrelate). In this study,
routine treatment is defined as saline hydration and
benefit of sarpogrelate is assessed as an adjunct to saline
hydration for the prevention of CIN following diagnos-
tic CAG or PCI
Study approval was given by the Ethics Committee/
Institutional Review Board of Seoul National University
Boramae Medical Center.
Participants
All patients with CKD scheduled for CAG will be eligi-
ble, assuming their ability to understand the character
and individual consequences of participation as well as
giving written informed consent. CKD is defined as esti-
mated glomerular filtration rate (eGFR) <60 mL/min per
1.73 m
2 using modification of diet in renal disease
(MDRD) formula or serum creatinine (Cr) > 1.5 mg/dL.
The MDRD formula was defined in the following way.
Where the Cr concentration is in mg/dL:
eGFR 186 serum Cr Age 742 if female =× × × ()
−− 1 154 0 203 0
.. .
Exclusion criteria are age less than 20 years or more
than 85 years, liver cirrhosis greater than or equal to
Child class B, decreased serum platelet level
(< 100,000/uL), patients who received or are schedule to
receive percutaneous renal intervention, currently are
taking anticoagulation drug s ,u n a b l et og i v ei n f o r m e d
consent. Patients in shock, maintaining hemodialysis,
hemofiltration, peritoneal dialysis will be excluded.
Intervention
After a baseline measurement, all patients receive 0.9%
saline or 0.45% saline intravenously at 150 ml/hour at
least for 6 hours before and 6~8 hours after receiving
contrast agent. Patients in the treatment group receive
sarpogrelate 300 mg per day for 24 hours before expo-
sure to contrast agent. Sarpogrelate will be given for
4 weeks.
Recruitment of participants started in April 2010. The
process of the trial conduct is illustrated in Figure 2. No
additional risks for study patients are expected, since all
treatment is carried out within established standard
methods of CAG or intervention.
Primary Outcome Measurement
T h ep r i m a r yo u t c o m eo ft h es t u d yi st h ei n c i d e n c eo f
CIN, defined as either a greater than 25 percent increase
o fs e r u mC ro ra na b s o l u t ei n c r e a s ei ns e r u mC ro f
0.5 mg/dL within 48 hours after using contrast agent
[28,29]. Clinical endpoint measurements are conducted
in-hospital and at 4 weeks. Cr concentration is
Figure 1 Structure of sarpogrelate.
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after contrast exposure, and at 4 weeks.
Secondary Outcomes Measurement
Secondary outcomes are occurrence of CIN, perfor-
mance of hemodialysis or hemofiltration and bleeding
events at 4 weeks.
Adverse effects
Analysis of safety related data is performed with respect
to frequency of serious adverse events, frequency of ser-
ious adverse events stratified by causality and frequency
of morbidity in both treatment groups.
At each assessment patients are assessed to report bleed-
ing. Patients who experienced a bleeding event are further
Figure 2 Study design.
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Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO) bleeding criteria [30]. Severe bleeding
is defined as any intracranial hemorrhage or bleeding that
causes hemodynamic compromise and requires interven-
tion. Moderate bleeding is defined as bleeding requiring
transfusion but does not result in hemodynamic compro-
mise. Mild bleeding is defined as bleeding that does not
meet criteria for either severe or moderate bleeding. Ser-
ious adverse events (SAE) have to be reported by the
attending physician to the principal investigator within 24
hours after the SAE becomes known.
Withdrawals
Patients are free to withdraw trial participation at their
own request at any time and without giving reasons for
their decision. Moreover, the primary investigator can
withdraw study patients, if continuation of the trial
would be detrimental to the patient’s well being. With-
drawals will be documented in the Case report form
(CRF) and in the patient’s medical records and all
ongoing SAE have to be followed up.
Sample size
The sample size calculation is based on the primary out-
come and the primary analysis for the intention-to-treat
population. The sample size is calculated using the
study’s primary objective to detect a 50% difference of
CIN occurrence between routine treatment with sarpo-
grelate and without sarpogrelate in a power of 80% to
demonstrate difference. We assumed that the expected
rate of CIN would be 20% in the control group [11].
We adjust the sample size for an estimated follow-up
loss rate of 10%, a two-sided level of significance
a =5 %a n dap o w e ro f1 - b = 80%, which result in
134 patients in each group is required to detect this
difference with a two-sided Student’s t- test. A total of 268
patients will be randomized and included in the analysis.
Randomization
Random assignments are generated using Excel spread-
sheet software (Microsoft Corporation, Redmont, USA).
Eligible patients are randomly assigned in a 1:1 ratio to
receive routine treatment with sarpogrelate or routine
treatment without sarpogrelate. Randomization is per-
formed by a personnel not involved in the study and kept
concealed.
Statistical analysis
The statistical analyses are performed on an intention-
to-treat basis. The two-sided null-hypothesis for the pri-
mary outcome measure states that sarpogrelate has the
potential effect on preventing CIN in CKD patients
undergoing CAG or PCI. Descriptive statistics will be
calculated according to the scale level of the variables.
The Kaplan- Meier method is used to plot the time to
the first episode of CIN, performance of hemodialysis or
hemofiltration and bleeding events after CAG or PCI.
Continuous data will be analyzed using Student’s
t-test. The chi-square test is used for categorical vari-
ables. A value of p < 0.05 is considered statistically sig-
nificant. Efficacy analyses was performed on the full
analysis set, which consist of patients who received at
least 1 dose of study medication. Patients who take the
medication at least once are analyzed for safety. Graphi-
cal methods including scatter plots and boxplots will be
used to visualize the findings of the trial.
The safety analysis includes calculation of frequencies
and rates of complications and serious adverse events
reported in the two groups. All analyses will be done
using SPSS Version 16.0 or higher.
Approval
This study follows the Helsinki Declaration’sp r i n c i p l e s ,
meaning that all patients sign a written informed con-
sent stating that participation is voluntary and that par-
ticipation can be withdrawn at any time, without any
negative consequences concerning their current or
future medical treatment. This study protocol was
approved by the institutional review board of Seoul
National University Boramae Medical Center.
Discussion
Sarpogrelate has shown promising results in animal stu-
dies and clinical trials. Recent studies show that this
drug has renal protective effect, however, its effects is
still not fully understood.
In this study, we examine the hypothesis that sarpo-
grelate has the prophylactic potential in CIN based on
the results of previous trials. The present study is small
and short-term clinical trial but the first trial investigat-
ing whether sarpogrelate has an effect on preventing
CIN in CKD patients undergoing CAG or PCI.
If the potential effects of sarpogrelate on these events
a r ep r o v e d ,t h er e s u l to fp r e s e n ts t u d ym a yp r o v i d ea n
inexpensive, safe, practical, and simple method for pre-
venting CIN other than saline hydration.
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